List of Excipients in Branded Drug FLUVOXAMINE MALEATE EXTENDED-RELEASE

« Back to Dashboard

Generic Drugs Containing FLUVOXAMINE MALEATE EXTENDED-RELEASE

Company	Ingredient	NDC	Excipient
Zydus Pharmaceuticals USA Inc	fluvoxamine maleate extended-release	70710-1847	D&C RED NO. 28
Zydus Pharmaceuticals USA Inc	fluvoxamine maleate extended-release	70710-1847	ETHYLCELLULOSE
Zydus Pharmaceuticals USA Inc	fluvoxamine maleate extended-release	70710-1847	FD&C BLUE NO. 1
Zydus Pharmaceuticals USA Inc	fluvoxamine maleate extended-release	70710-1847	FERRIC OXIDE YELLOW
Zydus Pharmaceuticals USA Inc	fluvoxamine maleate extended-release	70710-1847	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in FLUVOXAMINE MALEATE EXTENDED-RELEASE?

# Of NDCs	Excipient
2	D&C RED NO. 28
2	ETHYLCELLULOSE
2	FD&C BLUE NO. 1
2	FERRIC OXIDE YELLOW
2	FERROSOFERRIC OXIDE

Fluvoxamine Maleate Extended-Release: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 8, 2026

Fluvoxamine maleate extended-release is an oral multiparticulate formulation used primarily for obsessive-compulsive disorder. The commercial opportunity is formulation-driven rather than molecule-driven. A viable product must reproduce the reference product’s release profile, bead-coating performance, capsule fill uniformity, food-effect profile, and tolerability while controlling polymer, coating, and manufacturing costs.

The strongest opportunities are generic substitution, second-source supply, low-cost coated-pellet manufacturing, and differentiated strengths or packaging. The main barriers are bioequivalence against an extended-release reference product, dissolution similarity across multiple time points, and reliable scale-up of coated drug-layered particles.

What is fluvoxamine maleate extended-release?

Fluvoxamine is a selective serotonin reuptake inhibitor. The extended-release product is marketed in the United States as Luvox CR, with 100 mg and 150 mg capsules. The FDA-approved indication is obsessive-compulsive disorder in adults. The product is administered once daily and is designed to release fluvoxamine over an extended period rather than deliver the full dose immediately.[1]

Attribute	Reference product profile
Active ingredient	Fluvoxamine maleate
Dosage form	Extended-release capsule
Strengths	100 mg and 150 mg
Primary indication	Obsessive-compulsive disorder
Administration	Once daily
FDA application	NDA 021519
Formulation platform	Multiparticulate coated beads or pellets in a capsule
Regulatory pathway for copies	ANDA, subject to FDA requirements
Biosimilar exposure	None; this is a small-molecule drug

The capsule is not a simple matrix tablet. The multiparticulate platform permits a large number of coated units to distribute through the gastrointestinal tract. That architecture can reduce the consequences of local defects in individual particles, but it creates demanding controls for particle-size distribution, coating weight gain, and dissolution.

What excipients are used in fluvoxamine extended-release capsules?

Public labeling identifies excipient classes associated with the Luvox CR capsule and its multiparticulate delivery system. The precise quantitative formulation and process parameters are generally proprietary.

The relevant excipient functions are:

Excipient class	Likely function in the formulation	Commercial significance
Sugar spheres or inert cores	Substrate for drug layering	Controls bead size and coating surface area
Povidone or related binder	Adheres fluvoxamine to the core	Affects drug loading and mechanical strength
Hypromellose	Drug-layer binder or film-forming component	Influences hydration and coating integrity
Ethylcellulose	Rate-controlling polymer	Primary release-control material
Talc	Anti-tacking and coating aid	Reduces agglomeration during fluid-bed processing
Triethyl citrate or comparable plasticizer	Improves polymer-film flexibility	Reduces cracking and supports stable release
Capsule shell gelatin or hypromellose	Encloses coated pellets	Affects moisture protection and capsule compatibility
Titanium dioxide and colorants	Capsule identification	Supports product differentiation and stability

The commercial formulation question is not whether a manufacturer can substitute one excipient for another. It is whether the substituted excipient produces the same drug-release mechanism and equivalent in vivo performance.

Which excipient attributes matter most?

Critical material attributes include:

• Sugar-sphere diameter and friability.
• Fluvoxamine particle size and solubility.
• Binder viscosity and concentration.
• Ethylcellulose viscosity grade.
• Polymer-to-drug ratio.
• Plasticizer level.
• Talc particle size and surface treatment.
• Coating suspension solids content.
• Pellet moisture content.
• Capsule shell moisture permeability.

A change from one ethylcellulose grade to another can alter film permeability, pore formation, and dissolution. A change in talc level can affect coating uniformity and agglomeration. A different sugar-sphere size can change surface area and drug loading even when the nominal formulation percentages remain unchanged.

What excipient strategy is best for a generic product?

The most defensible strategy is a Q1/Q2-oriented formulation that uses the same functional excipient classes as the reference product, followed by targeted optimization of polymer grade, coating weight, and bead-size distribution.

A practical development sequence is:

1. Establish the reference product’s dissolution profile across acidic and neutral media.
2. Characterize pellet morphology, particle-size distribution, and coating thickness.
3. Build drug-layered cores using a high-uniformity binder system.
4. Apply a rate-controlling ethylcellulose-based film.
5. Optimize plasticizer and anti-tacking levels through design-of-experiments work.
6. Compare dissolution at multiple time points, including early, middle, and terminal release intervals.
7. Confirm pharmacokinetic equivalence under fasting and fed conditions where required.
8. Lock the process only after scale-up confirms coating uniformity.

The best commercial formulation is not necessarily the one with the fewest excipients. A lower-cost formulation that produces variable coating thickness can create repeated batch failures, supplement requests, or post-approval manufacturing constraints.

Can a manufacturer use alternative excipients?

Yes, subject to the regulatory pathway and product-specific requirements. Alternative excipients are most practical when they preserve the same functional mechanism. Examples include:

• A different viscosity grade of ethylcellulose.
• A different plasticizer compatible with the selected polymer.
• A substituted binder with equivalent drug-layering performance.
• A different capsule shell composition with comparable moisture behavior.

Substitution becomes more difficult when it changes the release mechanism, pellet architecture, or gastrointestinal behavior. A tablet matrix, osmotic system, or lipid-based system may require a more extensive development package than a multiparticulate coated-pellet formulation.

What manufacturing and intellectual-property barriers affect fluvoxamine ER?

The main manufacturing barrier is reproducible coating at commercial scale. Fluid-bed coating must control spray rate, atomization, inlet temperature, product temperature, air volume, and drying conditions. Small deviations can produce agglomeration, rough films, cracking, or an altered release curve.

Manufacturing risks include:

Risk	Effect on product
Uneven drug layering	Content-uniformity failures
Pellet agglomeration	Oversized particles and poor capsule fill
Excessive coating weight	Slow or incomplete release
Insufficient coating weight	Dose dumping or rapid release
Film cracking	Accelerated dissolution
Residual solvent or moisture	Stability and capsule-shell concerns
Pellet-size drift	Variable surface area and release
Poor blend segregation control	Capsule-to-capsule potency variation

The intellectual-property barrier is narrower than for a new chemical entity. The active ingredient is an established small molecule, so the competitive estate is concentrated in:

• Controlled-release pellet architecture.
• Polymer coating systems.
• Capsule compositions.
• Specific dissolution profiles.
• Manufacturing processes.
• Methods of treating OCD with once-daily extended-release fluvoxamine.
• Stability and packaging configurations.

What patents protect fluvoxamine maleate extended-release?

The original extended-release patent estate was directed to controlled-release fluvoxamine formulations rather than composition-of-matter protection for fluvoxamine itself. Public patent records associated with controlled-release fluvoxamine include U.S. patents in the 6.4 million and 7.1 million series, with expiration dates dependent on the individual patent, patent-term adjustment, terminal disclaimers, and any applicable regulatory patent-term extension.[2][3]

The commercially relevant distinction is between expired core formulation patents and any surviving later patents covering specific formulations, manufacturing methods, or methods of use. A generic applicant must evaluate the current FDA Orange Book listing and the full prosecution history before selecting Paragraph IV positions.[4]

Patent category	Relevance to a generic applicant
Compound patent	Limited relevance because fluvoxamine is an established active ingredient
Original controlled-release formulation patent	May have expired or reached late-life status
Later formulation patent	Can create a Paragraph IV or section viii strategy issue
Method-of-use patent	May require labeling carve-out or litigation assessment
Manufacturing patent	May be avoidable through process redesign
Packaging or stability patent	Usually manageable through alternative packaging

Patent expiration should not be inferred solely from the grant date. The relevant date can change because of patent-term adjustment, terminal disclaimers, reexamination history, or regulatory extensions.

When does fluvoxamine ER lose exclusivity?

FDA regulatory exclusivity and patent exclusivity are separate.

Luvox CR received approval in 2008. The reference product’s commercial protection therefore depends on the surviving Orange Book patents, any applicable pediatric exclusivity, and the availability of an approvable ANDA. A generic applicant may file an ANDA before patent expiration, but commercial launch depends on the certification selected, litigation outcomes, settlement terms, and any 180-day exclusivity held by a first filer.[1][4]

The principal launch scenarios are:

Scenario	Commercial outcome
No listed patent barrier	Launch after FDA approval and ordinary regulatory clearance
Paragraph III certification	Approval may be delayed until the certified patent expires
Paragraph IV certification with no suit	Launch after the statutory waiting period and approval
Paragraph IV certification followed by timely suit	Approval may be subject to a 30-month stay, unless resolved earlier
Settlement with licensed entry	Launch occurs on the negotiated date and terms
First-to-file generic	Potential 180-day generic exclusivity

The current Orange Book should control any definitive conclusion about listed patents, expiration dates, and exclusivity. A formulation strategy should not rely on an old patent list because Orange Book entries and regulatory status can change.

What is the Orange Book status of fluvoxamine maleate extended-release?

The FDA Orange Book identifies approved drug applications, reference listed drugs, patent information, and exclusivity data. Luvox CR is the relevant reference product for U.S. extended-release fluvoxamine capsules.[4]

For a generic applicant, the critical Orange Book review covers:

• The reference listed drug designation.
• Approved strengths.
• Active patent listings.
• Patent-use codes.
• Any pediatric exclusivity.
• Approved ANDA applicants.
• Discontinued or withdrawn application status.
• Whether the reference product remains commercially available.

A generic applicant must match the reference product’s dosage form and route. An immediate-release fluvoxamine product is not an automatic substitute for an extended-release capsule. The ANDA must address the extended-release performance and labeling requirements applicable to the reference product.

Are there Paragraph IV challenges or fluvoxamine ER litigation?

Paragraph IV exposure depends on whether a current Orange Book-listed patent remains enforceable and whether an applicant files a Paragraph IV certification. The principal legal risks are infringement allegations involving controlled-release coating systems, pellet compositions, and method-of-use claims.

No reliable commercial conclusion should be drawn from the historical existence of a patent lawsuit alone. The operative questions are:

1. Was the patent listed for the reference product?
2. Was a Paragraph IV notice letter served?
3. Was a timely infringement complaint filed?
4. Did the litigation trigger a 30-month stay?
5. Was the case dismissed, settled, or adjudicated?
6. Did the settlement impose a delayed-entry date or supply restriction?

Patent litigation databases and FDA records should be read together because court dockets establish litigation events, while the Orange Book controls listed-patent and certification context.

What commercial opportunities exist for fluvoxamine ER excipients?

The highest-value opportunities are specialized rather than volume-driven.

Functional excipient supply

Suppliers can target:

• High-purity ethylcellulose grades.
• Consistent sugar spheres.
• Low-variability hypromellose.
• Pharmaceutical-grade plasticizers.
• Anti-tacking systems for fluid-bed coating.
• Moisture-control packaging materials.

The key selling point is batch-to-batch release consistency, not simply excipient price.

Contract development and manufacturing

A CDMO with fluid-bed coating, drug layering, and multiparticulate encapsulation capabilities can compete for:

• ANDA development.
• Product transfers.
• Second-source manufacturing.
• Regional licensing.
• Lifecycle reformulation.
• Small-batch clinical or bridging supplies.

A CDMO that can demonstrate scale-up from laboratory coating to commercial equipment has a stronger position than a conventional tablet manufacturer.

Regional generic licensing

Fluvoxamine ER may support regional opportunities where OCD treatment is established but extended-release competition is limited. Commercial attractiveness depends on local registration requirements, reference-product availability, reimbursement, and the ability to obtain comparative bioavailability data.

Reformulation opportunities

Potential differentiated products include:

• Alternative capsule strengths.
• Sprinkle-compatible multiparticulates, if supported by data and labeling.
• Lower-cost packaging for high-volume markets.
• Moisture-protected unit-dose packaging.
• Fixed-dose or combination products, although combination development would require a separate clinical and regulatory strategy.

A modified-release product with a new release profile would generally move beyond a straightforward generic opportunity and could require a 505(b)(2) pathway in the United States.

How does fluvoxamine ER compare with competing antidepressant formulations?

Fluvoxamine ER has a narrower approved commercial market than extended-release formulations of venlafaxine, bupropion, or paroxetine. Its primary differentiation is once-daily OCD treatment rather than broad depression use.

Product category	Formulation opportunity	Competitive position
Fluvoxamine ER	Coated multiparticulate capsule	Narrow OCD-focused market
Fluvoxamine immediate release	Conventional tablet or capsule	Greater dosing flexibility, more fluctuation
Venlafaxine ER	Matrix or bead-based extended release	Larger depression and anxiety market
Bupropion XL	Matrix extended-release tablet	Larger market and stronger generic competition
Paroxetine CR	Controlled-release tablet	Broader historical indication set

Fluvoxamine ER can still be attractive when manufacturing cost is low and the applicant has a credible path to bioequivalence. The smaller market reduces expected sales but may also limit the number of serious competitors.

What generic launch risks exist?

The principal risks are:

• Failure to match the reference dissolution curve.
• Food-effect differences.
• Delayed FDA review caused by formulation deficiencies.
• Patent litigation or an Orange Book certification dispute.
• Limited market size after launch.
• Reference-product discontinuation or supply disruption.
• Physician and payer preference for immediate-release fluvoxamine or other SSRIs.
• Manufacturing losses from pellet agglomeration and coating variability.

Revenue exposure for a generic entrant is likely to be concentrated in the first years after launch, before additional ANDA approvals reduce pricing. The strongest launch economics arise from first approval, limited competition, reliable supply, and a low-cost multiparticulate process.

What is the overall patent strength of fluvoxamine ER?

The patent estate is likely moderate to weak for the original active ingredient and stronger only where surviving claims cover a narrow controlled-release formulation or difficult-to-design-around process.

Estate component	Relative strength
Fluvoxamine composition of matter	Low, based on age of the molecule
Original ER concept	Low to moderate, depending on remaining term
Specific pellet-coating claims	Moderate if technically narrow and still enforceable
Method-of-use claims	Moderate, but potentially addressable through labeling
Manufacturing claims	Variable; often avoidable through process redesign
Excipient-only claims	Usually limited unless tied to a defined release profile

The strongest defensive position would combine formulation claims with process claims and demonstrate that commercially practical alternatives reproduce the required pharmacokinetic profile. A single broad controlled-release claim is less durable when the underlying technology is mature.

Key Takeaways

• Fluvoxamine maleate extended-release is a multiparticulate, coated-pellet product rather than a simple matrix dosage form.
• Ethylcellulose, hypromellose, binders, plasticizers, talc, and inert cores are the principal excipient and process levers.
• The highest technical risk is commercial-scale coating uniformity.
• Generic development should prioritize reference dissolution characterization, particle-size control, and fed-versus-fasted bioequivalence.
• The core composition-of-matter estate for fluvoxamine is not the main barrier; formulation, process, and method-of-use rights are more relevant.
• FDA Orange Book data and current court records are necessary to determine active patent barriers and Paragraph IV exposure.
• The commercial opportunity is best suited to companies with multiparticulate manufacturing expertise, low-cost coated-pellet production, or regional licensing capability.
• Biosimilar risk does not apply because fluvoxamine is a small-molecule drug.
• Revenue potential is narrower than for major antidepressant extended-release products, but competition may also be less concentrated.

FAQs

Is fluvoxamine maleate extended-release a biologic?

No. Fluvoxamine is a small-molecule active pharmaceutical ingredient. The relevant approval route is an ANDA for a therapeutically equivalent generic, or potentially a 505(b)(2) application for a materially different formulation.

Can fluvoxamine ER be developed as a tablet instead of a capsule?

Potentially, but a tablet would need to demonstrate equivalent extended-release performance. A matrix tablet would not automatically qualify as an equivalent dosage form or formulation platform.

Which excipient is most important for fluvoxamine ER release control?

Ethylcellulose or another rate-controlling polymer is generally the most important release-control component. Its grade, coating weight, plasticization, and porosity determine the release profile.

Is a Paragraph IV challenge required for generic fluvoxamine ER?

Not necessarily. The certification depends on the current Orange Book patent listings and the applicant’s assessment of each listed patent. A Paragraph III certification, section viii statement, or Paragraph IV certification may be appropriate depending on the patent and labeling position.

Is fluvoxamine ER a strong licensing opportunity?

It is a targeted opportunity rather than a broad blockbuster opportunity. The strongest licensing case is a combination of approved manufacturing capability, a validated multiparticulate process, low cost of goods, and access to a market with limited extended-release competition.

References

1. U.S. Food and Drug Administration. (2008). Luvox CR prescribing information.
2. U.S. Patent and Trademark Office. (n.d.). Patent Center: Controlled-release fluvoxamine patent records.
3. U.S. National Library of Medicine. (n.d.). Drug and patent information for fluvoxamine extended-release formulations.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.